Kairos Pharma KAPA
NYSE KAPA
$0.60 +0.02 (+2.71%)
As of: Oct 21, 2026 · 3:59 PM EDT

Kairos Pharma (KAPA) EBIT Margin (2025)

Updated

Kairos Pharma's EBIT Margin came in at -5.57% for FY2025, down 3.23 percentage points from -2.34% in FY2024.

Analysis

Kairos Pharma (KAPA) EBIT Margin (2025) Analysis & Trends

  • Per Business Quant, earlier years put EBIT Margin at -2.34% in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 28.21%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 37.86%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -3.52%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 32.97%
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 20.57%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 34.95%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -133.21%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 28.37%
10 Kairos Pharma 10.86 Mn -1.55 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 -1.27%
API Access

Kairos Pharma EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=KAPA&period=max&api_key=YOUR_API_KEY